Triplet Not Always Better Than Doublet in mCSPC

First-line systemic therapy in patients with metastatic castration-sensitive prostate cancer should be based on individual disease and patient characteristics, results of a meta-analysis suggest.
Medscape Medical News

source https://www.medscape.com/viewarticle/989059?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?